Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes
Abstract Chimeric antigen receptor (CAR) T cell therapy is now approved for the standard of care treatment of several types of relapsed or refractory hematologic malignancies. Future advances may extend cellular therapies to solid tumors or even non‐malignant diseases. As patient need grows, a clini...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.357 |
| _version_ | 1828716035674472448 |
|---|---|
| author | Michael D. Jain Jay Y. Spiegel |
| author_facet | Michael D. Jain Jay Y. Spiegel |
| author_sort | Michael D. Jain |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) T cell therapy is now approved for the standard of care treatment of several types of relapsed or refractory hematologic malignancies. Future advances may extend cellular therapies to solid tumors or even non‐malignant diseases. As patient need grows, a clinical specialty of “cell therapy” may emerge. Here, we envision the needs of a clinical cell therapist to monitor and intervene upon patients receiving cell therapies. These include: (1) monitoring patient T cell quality and the host immune environment to ensure optimal timing for cell therapy. (2) Tumor antigen profiling to personalize CAR T cell targeting. (3) Real‐time monitoring of CAR T cells and circulating tumor DNA to modulate CAR T cell activity to maximize tumor eradication while mitigating toxicity. (4) Monitoring of CAR rejection and anti‐CAR immunity posttreatment to inform re‐dosing and subsequent cell therapy strategies. Armed with these tools, the future Cell Therapist may optimize and personalize treatment to avoid toxicity and improve efficacy universally across CAR designs. |
| first_indexed | 2024-03-12T14:05:37Z |
| format | Article |
| id | doaj.art-481ef2690c094004b453b9f5f78bd024 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:05:37Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-481ef2690c094004b453b9f5f78bd0242023-08-21T14:10:16ZengWileyeJHaem2688-61462022-01-013S1465310.1002/jha2.357Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomesMichael D. Jain0Jay Y. Spiegel1Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center, and Department of Oncologic Sciences Morsani College of Medicine University of South Florida Tampa Florida USADivision of Transplant and Cellular Therapy Sylvester Comprehensive Cancer Center University of Miami Miami Florida USAAbstract Chimeric antigen receptor (CAR) T cell therapy is now approved for the standard of care treatment of several types of relapsed or refractory hematologic malignancies. Future advances may extend cellular therapies to solid tumors or even non‐malignant diseases. As patient need grows, a clinical specialty of “cell therapy” may emerge. Here, we envision the needs of a clinical cell therapist to monitor and intervene upon patients receiving cell therapies. These include: (1) monitoring patient T cell quality and the host immune environment to ensure optimal timing for cell therapy. (2) Tumor antigen profiling to personalize CAR T cell targeting. (3) Real‐time monitoring of CAR T cells and circulating tumor DNA to modulate CAR T cell activity to maximize tumor eradication while mitigating toxicity. (4) Monitoring of CAR rejection and anti‐CAR immunity posttreatment to inform re‐dosing and subsequent cell therapy strategies. Armed with these tools, the future Cell Therapist may optimize and personalize treatment to avoid toxicity and improve efficacy universally across CAR designs.https://doi.org/10.1002/jha2.357cell therapylymphomasmyeloma |
| spellingShingle | Michael D. Jain Jay Y. Spiegel Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes eJHaem cell therapy lymphomas myeloma |
| title | Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes |
| title_full | Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes |
| title_fullStr | Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes |
| title_full_unstemmed | Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes |
| title_short | Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes |
| title_sort | imagining the cell therapist future car t cell monitoring and intervention strategies to improve patient outcomes |
| topic | cell therapy lymphomas myeloma |
| url | https://doi.org/10.1002/jha2.357 |
| work_keys_str_mv | AT michaeldjain imaginingthecelltherapistfuturecartcellmonitoringandinterventionstrategiestoimprovepatientoutcomes AT jayyspiegel imaginingthecelltherapistfuturecartcellmonitoringandinterventionstrategiestoimprovepatientoutcomes |